Bloomberg Law
Drug, Device Manufacturers to Face Hill Scrutiny in 2019
January 8, 2019
Summary
Combating high drug and device prices is a bipartisan goal in Congress, and House Democrats in control of key oversight committees have made clear their plans to pursue investigations putting pharma CEOs under scrutiny. Manufacturers need to prep now to explain policies and prepare for public relations issues.
Authors:
Jaime L.M. Jones
Contacts
Related Capabilities
SERVICES AND INDUSTRIES
Stay Up To Date